HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Harmony Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$37.54−0.41 (-1.08%)
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Share price
+$11.64 (+44.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Harmony Biosciences Holdings, Inc. grew revenue 24.3% to $959.90M over the twelve months to Jun 30, 2026. Operating income rose 4.0% to $230.65M, moving the operating margin from 28.7% to 24.0%. Free cash flow was $347.89M, up 59.1% from a year earlier.
Revenue
$959.90M
+24.3% vs. a year earlier
Operating income
$230.65M
+4.0% vs. a year earlier
Free cash flow
$347.89M
+59.1% vs. a year earlier
EPS, diluted
$3.09
-0.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.21B
- P/E ratio
- 12.1
- Price to sales
- 2.30
- Price to book
- 2.21
- Dividend yield
- –
- Free cash flow yield
- 15.77%
Fundamentals
- Revenue
- $959.90M
- Net income
- $181.27M
- EPS, diluted
- $3.09
- Free cash flow
- $347.89M
- Book value per share
- $17.01
- Diluted shares
- 59M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$959.90M+24.3% YoY
Gross profit
$723.99M+19.6% YoY
Operating income
$230.65M+4.0% YoY
Net income
$181.27M+0.2% YoY
EPS, diluted
$3.09-0.3% YoY
Free cash flow
–
Reported periodTrailing twelve months